Nanjing Vazyme Biotech Co., Ltd. (688105.SS)
CNY 23.21
(-1.9%)
CNY 23.21
(-1.9%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -100.18 Million CNY | -123.38% |
| 2022 | 1.19 Billion CNY | 55.42% |
| 2021 | 771.13 Million CNY | -20.75% |
| 2020 | 973.01 Million CNY | 3901.05% |
| 2019 | 24.31 Million CNY | 4522.32% |
| 2018 | 526.12 Thousand CNY | 11535.7% |
| 2017 | 4521.61 CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -25.75 Million CNY | 66.68% |
| 2024 Q2 | -9.72 Million CNY | 62.25% |
| 2024 Q3 | -8.14 Million CNY | 16.25% |
| 2023 Q1 | -33.7 Million CNY | 73.87% |
| 2023 FY | -280.2 Million CNY | -123.38% |
| 2023 Q4 | -77.29 Million CNY | -910.77% |
| 2023 Q3 | 9.53 Million CNY | 123.83% |
| 2023 Q2 | -40 Million CNY | -18.7% |
| 2022 Q3 | 143.39 Million CNY | -27.57% |
| 2022 Q2 | 197.96 Million CNY | -60.81% |
| 2022 Q1 | 505.13 Million CNY | 247.34% |
| 2022 FY | 1.19 Billion CNY | 55.42% |
| 2022 Q4 | -128.99 Million CNY | -189.96% |
| 2021 Q3 | 177.56 Million CNY | 213.73% |
| 2021 Q1 | 391.54 Million CNY | 58.32% |
| 2021 Q2 | 56.59 Million CNY | -85.55% |
| 2021 FY | 771.13 Million CNY | -20.75% |
| 2021 Q4 | 145.42 Million CNY | -18.1% |
| 2020 Q1 | 135.25 Million CNY | 0.0% |
| 2020 FY | 973.01 Million CNY | 3901.05% |
| 2020 Q3 | 183.51 Million CNY | -54.9% |
| 2020 Q2 | 406.93 Million CNY | 200.85% |
| 2020 Q4 | 247.31 Million CNY | 34.77% |
| 2019 FY | 24.31 Million CNY | 4522.32% |
| 2018 FY | 526.12 Thousand CNY | 11535.7% |
| 2017 FY | 4521.61 CNY | 0.0% |